射频消融作为肝细胞癌一线治疗的20年生存评估
该研究纳入2000至2020年间505例连续接受超声引导经皮射频消融作为一线治疗的肝细胞癌患者,按2011年抗病毒治疗纳入医保前后分为第一个十年和第二个十年两组。第二个十年组患者更年轻、肿瘤更小、Child-Pugh评分更低且抗病毒治疗比例更高,倾向性评分匹配后第二个十年组无进展生存期改善(中位68 vs 49个月),但总生存期无显著差异(中位71 vs 65个月)。
要点
- 第二个十年组无进展生存期较第一个十年组改善,中位68 vs 49个月(p=.003)。
- 两组总生存期无显著差异,中位71 vs 65个月(p=.20)。
- 初始射频消融技术成功率为96.0%,共完成726次消融治疗867个病灶。
核心结论
- 第二个十年接受射频消融作为一线治疗的肝细胞癌患者无进展生存期改善,但长期总生存期较第一个十年无显著增加,提示射频消融治疗虽有进步但仍可能未实质性影响总生存。
研究设计与样本
- 研究为2000至2020年单中心连续队列,纳入505例接受超声引导经皮射频消融作为一线治疗的肝细胞癌患者,按2011年抗病毒治疗纳入国家医保前后分为第一个十年(2000-2010)和第二个十年(2011-2020)两组,采用Cox比例风险模型分析总生存预后因素,Kaplan-Meier法比较生存,并用倾向性评分匹配减少选择偏倚。
诊断标准与关键数值
- 共完成726次射频消融治疗867个肝细胞癌病灶,96.0%的患者从初始射频消融获得技术成功。
- 倾向性评分匹配后第二个十年组无进展生存期中位68个月 vs 第一个十年组49个月(p=.003)。
- 倾向性评分匹配后两组总生存期中位71 vs 65个月(p=.20),无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the changes in clinical characteristics, overall survival (OS), and progression-free survival (PFS) by investigating a 20-year cohort of patients with HCC who underwent RFA treatment.
METHODS: From 2000 to 2020, 505 consecutive patients with HCC underwent ultrasound-guided percutaneous RFA as first-line therapy at a tertiary cancer hospital. We divided the cohort according to the time when hepatitis-B antiviral therapy was covered by national medical insurance coverage (early 2011), including the first decade (2000-2010) and second decade (2011-2020). The prognostic factors for OS were analyzed by the Cox proportional hazard model. OS and PFS in different groups were compared using the Kaplan-Meier method. To reduce selection bias, matched groups of patients were selected using the propensity score matching (PSM) method.
RESULTS: In total, 726 RFA sessions were performed to treat 867 HCC lesions. Patients treated in the second decade were younger (p =.047), had smaller tumors (p <.001), had lower Child-Pugh scores (p <.001), and had a higher proportion of antiviral treatment (p <.001). A total of 96.0% of patients achieved technical efficacy from the initial RFA. After PSM analysis, improved PFS was found for the second decade (median, 68 vs. 49 months, p =.003), but no significant difference in OS was observed between the two groups (median, 71 vs. 65 months, p =.20).
CONCLUSIONS: This study demonstrated that improved PFS was achieved in patients with HCC receiving RFA as first-line treatment in the second decade. However, long-term OS was not significantly increased compared to the first decade suggesting that while RFA treatment has improved, it still might not substantially affect OS results.
引用
- Bai XM, He ZH, Wu H, et al. An evaluation of 20-year survival of radiofrequency ablation for hepatocellular carcinoma as first-line treatment. Eur J Radiol. 2023. PMID: 37738836. doi:10.1016/j.ejrad.2023.111094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。